Comparative effectiveness and safety of medications for type 2 diabetes: An update including new drugs and 2-drug combinations

Wendy Bennett, Nisa Maruthur, Sonal Singh, Jodi Segal, Lisa Wilson, Ranee Chatterjee, Spyridon Marinopoulos, Milo A. Puhan, Padmini Ranasinghe, Lauren Block, Wanda K. Nicholson, Susan Hutfless, Eric B Bass, Shari Bolen

Research output: Contribution to journalArticle

Abstract

Background: Given the increase in medications for type 2 diabetes mellitus, clinicians and patients need information about their effectiveness and safety to make informed choices. Purpose: To summarize the benefits and harms of metformin, second-generation sulfonylureas, thiazolidinediones, meglitinides, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 receptor agonists, as monotherapy and in combination, to treat adults with type 2 diabetes. Data Sources: MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials were searched from inception through April 2010 for English-language observational studies and trials. The MEDLINE search was updated to December 2010 for long-term clinical outcomes. Study Selection: Two reviewers independently screened reports and identified 140 trials and 26 observational studies of head-tohead comparisons of monotherapy or combination therapy that reported intermediate or long-term clinical outcomes or harms. Data Extraction: Two reviewers following standardized protocols serially extracted data, assessed applicability, and independently evaluated study quality. Data Synthesis: Evidence on long-term clinical outcomes (all-cause mortality, cardiovascular disease, nephropathy, and neuropathy) was of low strength or insufficient. Most medications decreased the hemoglobin A1c level by about 1 percentage point and most 2-drug combinations produced similar reductions. Metformin was more efficacious than the DPP-4 inhibitors, and compared with thiazolidinediones or sulfonylureas, the mean differences in body weight were about -2.5 kg. Metformin decreased low-density lipoprotein cholesterol levels compared with pioglitazone, sulfonylureas, and DPP-4 inhibitors. Sulfonylureas had a 4-fold higher risk for mild or moderate hypoglycemia than metformin alone and, in combination with metformin, had more than a 5-fold increased risk compared with metformin plus thiazolidinediones. Thiazolidinediones increased risk for congestive heart failure compared with sulfonylureas and increased risk for bone fractures compared with metformin. Diarrhea occurred more often with metformin than with thiazolidinediones. Limitations: Only English-language publications were reviewed. Some studies may have selectively reported outcomes. Many studies were small, were of short duration, and had limited ability to assess clinically important harms and benefits. Conclusion: Evidence supports metformin as a first-line agent to treat type 2 diabetes. Most 2-drug combinations similarly reduce hemoglobin A1C levels, but some increased risk for hypoglycemia and other adverse events. Primary Funding Source: Agency for Healthcare Research and Quality.

Original languageEnglish (US)
Pages (from-to)602-618
Number of pages17
JournalAnnals of Internal Medicine
Volume154
Issue number9
StatePublished - May 3 2011

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine

Cite this